Clinical trials: Eczema
Atopic Dermatitis
A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) previously treated with Dupilumab.
- Trial name
- ADapt (NCT05369403)
- Testing
- Lebrikizumab
- Where
- 37 sites in United States
- Volunteers
- 86 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis, Atopic Dermatitis (AD)
Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis
This Phase 3 study is designed to evaluate the efficacy and safety of once-daily roflumilast cream 0.3% in children, adolescents, and adults with moderate to severe atopic dermatitis.
- Conditions
- Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema)
- Trial name
- INTEGUMENT 3 (NCT07916480)
- Testing
- Roflumilast Cream 0.3%, Vehicle Cream
- Where
- United States
- Volunteers
- 415 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Atopic Dermatitis
A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab
This is a long-term study to collect data over 3 years in order to find out what is likely to happen in the future regarding participants 6 years of age and older who receive dupilumab for Atopic Dermatitis (AD) commonly known as…
- Trial name
- DUPILAB (NCT06169527)
- Testing
- Dupilumab
- Where
- 42 sites in France
- Volunteers
- 303 people
- Sponsor
- Sanofi
Atopic Dermatitis
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis.
- Trial name
- NCT06807281
- Testing
- Abrocitinib
- Where
- 39 sites in United States, China and 5 more
- Volunteers
- 450 people
- Sponsor
- Pfizer
Atopic Dermatitis
Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis
Primary objective: To evaluate the efficacy of tralokinumab in combination with topical corticosteroids (TCS) compared with placebo in combination with TCS in treating moderate-to-severe atopic dermatitis (AD).
- Trial name
- ECZTRA 8 (NCT04587453)
- Testing
- Tralokinumab, Topical corticosteroids (TCS)
- Where
- 25 sites in Japan
- Volunteers
- 106 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
A Phase I Clinical Study to Evaluate SM17 in Chinese Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis
This trial is a phase 1, randomized, double-blind, placebo-controlled trial conducted in Chinese Healthy Volunteers and Patients with moderate-to-severe Atopic Dermatitis It aims to evaluate the safety, tolerability…
- Trial name
- NCT07103369
- Testing
- SM17 for injection
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- SinoMab BioScience Ltd
Atopic Dermatitis
Efficacy of the "Атопик Soothing Cream" in Children With Mild to Moderate Atopic Dermatitis
A Double-Blind Randomized Placebo-Controlled Trial to Evaluate the Efficacy of the "Атопик Soothing Cream" in Children with Mild to Moderate Atopic Dermatitis
- Trial name
- NCT02716181
- Testing
- "Атопик Soothing Cream"
- Where
- Russia
- Volunteers
- 74 people
- Sponsor
- Avanta Trading Ltd.
Dermatitis, Atopic
WAL 801 CL Dry Syrup in Paediatric Atopic Dermatitis Patients
Study to investigate the safety and efficacy of WAL 801 CL Dry Syrup on pruritus associated with paediatric atopic dermatitis in comparison with that of Ketotifen Fumarate Dry Syrup and to confirm the appropriateness of dosage of…
- Trial name
- NCT02182557
- Testing
- WAL 801 CL Dry Syrup, Ketotifen Fumarate Dry Syrup
- Volunteers
- 162 people
- Sponsor
- Boehringer Ingelheim
Eczema
Randomised, Double-blind, Placebo-controlled Study of Topical Clobetasone Butyrate 0.05% Cream in Subjects With Eczema for Two Weeks to Evaluate the Efficacy and Safety
This was a multicenter, randomised, double-blind, two treatment arms, vehicle (cream base) -controlled, parallel-group study in subjects with moderate to severe eczema (defined by investigators global assessment (IGA) score…
- Trial name
- NCT01567995
- Testing
- Clobetasone Butyrate 0.05% Cream, Vehicle (base cream)
- Where
- 7 sites in China
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis, Healthy
Pilot Tape Harvesting Study
The main objectives of the study are: To determine if RNA recovery from tape harvesting allows for the identification of a disease gene signature (e.g., interferon [IFN] signature for lupus) or other biomarkers that may…
- Conditions
- Atopic Dermatitis, Healthy, Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus
- Trial name
- NCT02125695
- Testing
- Skin Taping, Blood Sampling, Skin Biopsy
- Where
- 2 sites in United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Biogen
Atopic Dermatitis
A Study of E6005 in Japanese Patients With Atopic Dermatitis
The safety and pharmacokinetics of topical application with E6005 ointment compared to vehicle will be evaluated in Japanese male patients with atopic dermatitis.
- Trial name
- NCT01179880
- Testing
- E6005
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Organon and Co
Chronic Hand Eczema
Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema
This study will assess the safety and efficacy of ARQ-252 cream in subjects with chronic hand eczema
- Trial name
- NCT04378569
- Testing
- ARQ-252 cream 0.3%, ARQ-252 cream 0.1%, ARQ-252 Vehicle Cream
- Where
- 37 sites in United States, Australia and 1 more
- Volunteers
- 230 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Atopic Dermatitis
A Phase I/IIa Study to Investigate the GM-XANTHO in Healthy Volunteers and Atopic Dermatitis Patients
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GM-XANTHO in Healthy Volunteers and to Investigate its Efficacy and Safety Profile in Atopic Dermatitis Patients
- Trial name
- NCT04369846
- Testing
- GM-XANTHO onitment
- Where
- 4 sites in Taiwan
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Xantho Biotechnology Co., LTD
Atopic Dermatitis
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.
- Trial name
- NCT03568331
- Testing
- Tradipitant
- Where
- 70 sites in United States
- Volunteers
- 375 people
- Sponsor
- Vanda Pharmaceuticals
Atopic Dermatitis
A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis
The purpose of this study is to compare the immunogenicity and safety of an investigational smallpox vaccine in subjects with atopic dermatitis to healthy volunteers.
- Trial name
- NCT00316602
- Testing
- IMVAMUNE
- Where
- 22 sites in United States, Mexico
- Volunteers
- 632 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Atopic Dermatitis
A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis
The purpose of this study is to evaluate the efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis.
- Trial name
- BREEZE-AD5 (NCT03435081)
- Testing
- Baricitinib
- Where
- 81 sites in United States, Canada and 1 more
- Volunteers
- 440 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis
The purpose of this study is to determine whether PR022 Topical Gels are safe and effective treatments for mild-to-moderate atopic dermatitis (AD).
- Trial name
- NCT03351777
- Testing
- PR022
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Realm Therapeutics, Inc.
Moderate-to-Severe Atopic Dermatitis
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as…
- Trial name
- ZENITH AD-1 (NCT07690371)
- Testing
- Rezpegaldesleukin
- Where
- 20 sites in United States
- Volunteers
- 510 people
- Sponsor
- Nektar Therapeutics
Atopic Dermatitis
Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
The main purpose of this Ph2a study is to evaluate the preliminary efficacy, safety and tolerability of GIA632 when administered to adult participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT07220577
- Testing
- GIA632
- Where
- 28 sites in United States, Bulgaria and 7 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
The Effects of Polyunsaturated Fatty Acids (PUFA) on Allergic/Atopic Dermatitis
This clinical trial will study the effects of PUFA supplementation during pregnancy and lactation period on fatty acid composition in human milk and plasma of the mothers and the clinical outcome of atopic dermatitis in infants…
- Trial name
- NCT01936194
- Testing
- DHA+EPA, High Olive Oil, DHA
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Mead Johnson Nutrition
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.